Anti-EphA2 CAR-T therapy / SenlangBio - LARVOL DELTA

Avalon GloboCare Announces its Planned Acquisition Target, SenlangBio, has Initiated First-In-Human Clinical Trial in Recurrent Brain Cancer (Avalon GloboCare Corp Press Release) - "Avalon GloboCare Corp...announced that its planned acquisition target, SenlangBio, has initiated a first-in-human clinical trial evaluating anti-EphA2 chimeric antigen receptor (CAR) T-cell therapy for recurrent glioblastoma...Three patients have received the starting dose of anti-EphA2 CAR-T in this dose-escalation trial....Prior to initiation of the clinical trial, SenlangBio successfully completed pre-clinical feasibility testing of its anti-EphA2 CAR-T and obtained Institution Review Board (IRB) approval from Xuanwu Hospital, the teaching hospital of Capital Medical University, Beijing, China, where the trial is being conducted (NIH clinical trial registration number: NCT03423992)."

Clinical • Trial status • Glioblastoma • Oncology